Clinical Trials | 29 July 2026
Parexel recognised among world's top disability inclusive businesses
Recognition highlights company's commitment to accessible workplaces and inclusive clinical research
Recognition highlights company's commitment to accessible workplaces and inclusive clinical research
The findings could significantly expand the number of patients eligible for targeted therapy
Merck said its strategy combines early generic licensing, regional manufacturing partnerships in Africa and Latin America
203-day study with ICMR to evaluate the efficacy and safety of the oral therapy in 164 patients with sickle cell disease
The treatment also produced statistically significant improvements in nail psoriasis severity compared with placebo
The SIGMA trial will assess GAMUNEX-C, an intravenous immunoglobulin
The BD-Ebov trial, led by Oxford Vaccine Group, will evaluate the safety and immune response of the ChAdOx1 BDBV vaccine in 50 healthy volunteers aged 18 to 55
The experimental therapy is designed to target seven tumor antigens commonly shared across multiple cancer types
No serious treatment-related adverse events observed in first 13 patients receiving ENV-105 with AstraZeneca's Tagrisso in Phase I study.
The first-line approval is backed by results from the Phase 3 BREAKWATER trial, which demonstrated that the cetuximab–encorafenib–FOLFOX combination delivered statistically significant and clinically meaningful improvements
The majority of participants also rated the denecimig pen-injector positively, with 94.1% of 185 participants describing it as easy or very easy to use and 89.7% reporting it was quick
This, after positive FDA feedback on neuropathic corneal pain program
The potential impact of the findings is particularly significant in episodic migraine, which represents a larger patient population than chronic migraine
The treatment effect emerged early and continued to build over time, with statistically significant improvement observed as soon as Day 64 and maintained through Week 24
The results come from two Phase 1/2 trials evaluating zoldonrasib both alongside standard chemotherapy in first-line patients and in combination with daraxonrasib in previously treated disease
The company said it has engaged with China’s Center for Drug Evaluation of the National Medical Products Administration and reached preliminary alignment regarding a potential registrational study for the ENRICH approach
Newron and the FDA discussed changes required for the study to potentially restart enrollment in the United States
Following a licensing agreement signed between the company and DNDi, a Phase III clinical trial to be conducted in Brazil, Malaysia, and Thailand
The proceeds will fund the planned early third-quarter 2026 launch of the global Phase 3 SURPASS-IPF trial
Subscribe To Our Newsletter & Stay Updated
